Craniofacial Bone Tissue Engineering: Current Approaches and Potential Therapy

Craniofacial bone defects can result from various disorders, including congenital malformations, tumor resection, infection, severe trauma, and accidents. Successfully regenerating cranial defects is an integral step to restore craniofacial function. However, challenges managing and controlling new...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Arbi Aghali
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	MSCs MKs growth factors BMP-2 TPO biomaterials Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/698ce1d954b543e59ef42a88b12cd324
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:698ce1d954b543e59ef42a88b12cd324
record_format	dspace
spelling	oai:doaj.org-article:698ce1d954b543e59ef42a88b12cd3242021-11-25T17:10:11ZCraniofacial Bone Tissue Engineering: Current Approaches and Potential Therapy10.3390/cells101129932073-4409https://doaj.org/article/698ce1d954b543e59ef42a88b12cd3242021-11-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/2993https://doaj.org/toc/2073-4409Craniofacial bone defects can result from various disorders, including congenital malformations, tumor resection, infection, severe trauma, and accidents. Successfully regenerating cranial defects is an integral step to restore craniofacial function. However, challenges managing and controlling new bone tissue formation remain. Current advances in tissue engineering and regenerative medicine use innovative techniques to address these challenges. The use of biomaterials, stromal cells, and growth factors have demonstrated promising outcomes in vitro and in vivo. Natural and synthetic bone grafts combined with Mesenchymal Stromal Cells (MSCs) and growth factors have shown encouraging results in regenerating critical-size cranial defects. One of prevalent growth factors is Bone Morphogenetic Protein-2 (BMP-2). BMP-2 is defined as a gold standard growth factor that enhances new bone formation in vitro and in vivo. Recently, emerging evidence suggested that Megakaryocytes (MKs), induced by Thrombopoietin (TPO), show an increase in osteoblast proliferation in vitro and bone mass in vivo. Furthermore, a co-culture study shows mature MKs enhance MSC survival rate while maintaining their phenotype. Therefore, MKs can provide an insight as a potential therapy offering a safe and effective approach to regenerating critical-size cranial defects.Arbi AghaliMDPI AGarticleMSCsMKsgrowth factorsBMP-2TPObiomaterialsBiology (General)QH301-705.5ENCells, Vol 10, Iss 2993, p 2993 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	MSCs MKs growth factors BMP-2 TPO biomaterials Biology (General) QH301-705.5
spellingShingle	MSCs MKs growth factors BMP-2 TPO biomaterials Biology (General) QH301-705.5 Arbi Aghali Craniofacial Bone Tissue Engineering: Current Approaches and Potential Therapy
description	Craniofacial bone defects can result from various disorders, including congenital malformations, tumor resection, infection, severe trauma, and accidents. Successfully regenerating cranial defects is an integral step to restore craniofacial function. However, challenges managing and controlling new bone tissue formation remain. Current advances in tissue engineering and regenerative medicine use innovative techniques to address these challenges. The use of biomaterials, stromal cells, and growth factors have demonstrated promising outcomes in vitro and in vivo. Natural and synthetic bone grafts combined with Mesenchymal Stromal Cells (MSCs) and growth factors have shown encouraging results in regenerating critical-size cranial defects. One of prevalent growth factors is Bone Morphogenetic Protein-2 (BMP-2). BMP-2 is defined as a gold standard growth factor that enhances new bone formation in vitro and in vivo. Recently, emerging evidence suggested that Megakaryocytes (MKs), induced by Thrombopoietin (TPO), show an increase in osteoblast proliferation in vitro and bone mass in vivo. Furthermore, a co-culture study shows mature MKs enhance MSC survival rate while maintaining their phenotype. Therefore, MKs can provide an insight as a potential therapy offering a safe and effective approach to regenerating critical-size cranial defects.
format	article
author	Arbi Aghali
author_facet	Arbi Aghali
author_sort	Arbi Aghali
title	Craniofacial Bone Tissue Engineering: Current Approaches and Potential Therapy
title_short	Craniofacial Bone Tissue Engineering: Current Approaches and Potential Therapy
title_full	Craniofacial Bone Tissue Engineering: Current Approaches and Potential Therapy
title_fullStr	Craniofacial Bone Tissue Engineering: Current Approaches and Potential Therapy
title_full_unstemmed	Craniofacial Bone Tissue Engineering: Current Approaches and Potential Therapy
title_sort	craniofacial bone tissue engineering: current approaches and potential therapy
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/698ce1d954b543e59ef42a88b12cd324
work_keys_str_mv	AT arbiaghali craniofacialbonetissueengineeringcurrentapproachesandpotentialtherapy
_version_	1718412654791360512

Craniofacial Bone Tissue Engineering: Current Approaches and Potential Therapy

Ejemplares similares